Compare Aecom (ACM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Regeneron Pharmaceuticals Inc — how do they compare? Aecom trades at $67.13 (market cap $9.42B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.8× Aecom's market cap, and Aecom pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| ACM | REGN | |
|---|---|---|
Market Cap | $9.42B | $83.19B |
Sector | Industrials | Health |
52-Week High | $134.35 | $812.27 |
52-Week Low | $66.86 | $545.94 |
Enterprise Value | $11.60B | $77.90B |
Dividend Yield | 1.62% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $75.84, up 1.21% daily, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings missed expectations with a loss of $0.50 per share, though revenue trends remain stable near $16 billion annually. The company secured new infrastructure projects in Australia and Portugal, supporting a record backlog. Valuation metrics show a P/E of 15.83 and P/S of 0.63, below sector averages, indicating potential undervaluation.
Outlook is mixed: strong analyst consensus (64% buy) and a $99.20 price target suggest 31% upside, but Q2 miss and rising debt-to-asset ratio (22.61% in 2025) pose risks. Investors should weigh robust contract wins against earnings volatility and macroeconomic pressures on infrastructure spending.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
